===============================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON DC 10549
---------------------------
FORM 10-QSB Amendment
---------------------------
Quarterly Report Under Section 13 of the Securities Exchange Act of 1934
For the Quarterly Period Ended Commission File No. 0-27282
JUNE 30, 1996
ATLANTIC PHARMACEUTICALS, INC.
142 Cypress Point Road
Half Moon Bay, California 94019
Telephone (415)726-1327
Incorporated in Delaware IRS ID # 36-3898269
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to
such filing requirements for the last 90 days:
Yes [x] No [ ]
2,913,720 shares of common stock $.001 par value are
outstanding on June 30, 1996
===============================================================================
SIGNATURES
- ----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf.
ATLANTIC PHARMACEUTICAL, INC.
October 9, 1996
Jon D. Lindjord
-------------------------------------
Jon D. Lindjord
Chief Executive Officer and President
Shimshon Mizrachi
-------------------------------------
Shimshon Mizrachi
Chief Financial Officer
Principal Accounting and Financial Officer
8